“…In a most recently published prospective cohort study that was not yet included in the systematic reviews and meta-analyses described above, HER2-low had a positive impact on survival also in HR-negative patients (HR 0.54, 95% CI 0.33–0.91, P = 0.02) irrespective of other key covariates (HR 0.48, 95% CI 0.27–0.83, P = 0.009) [ 18 ]. The authors concluded that these findings raised the possibility that HER2-low breast cancer may be a unique entity.…”